KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Cash from Operations (2016 - 2025)

Globus Medical (GMED) has disclosed Cash from Operations for 15 consecutive years, with 248587000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 18.18% year-over-year to 248587000.0, compared with a TTM value of 753447000.0 through Dec 2025, up 44.72%, and an annual FY2025 reading of 753447000.0, up 44.72% over the prior year.
  • Cash from Operations was 248587000.0 for Q4 2025 at Globus Medical, roughly flat from 249695000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 249695000.0 in Q3 2025 and bottomed at 32920000.0 in Q3 2022.
  • Average Cash from Operations over 5 years is 98616300.0, with a median of 63772500.0 recorded in 2021.
  • The sharpest move saw Cash from Operations crashed 57.39% in 2022, then soared 303.4% in 2024.
  • Year by year, Cash from Operations stood at 76253000.0 in 2021, then decreased by 16.1% to 63975000.0 in 2022, then surged by 63.62% to 104674000.0 in 2023, then surged by 100.95% to 210339000.0 in 2024, then increased by 18.18% to 248587000.0 in 2025.
  • Business Quant data shows Cash from Operations for GMED at 248587000.0 in Q4 2025, 249695000.0 in Q3 2025, and 77865000.0 in Q2 2025.